支气管哮喘中医证候时空演变规律和表征生物学的队列研究

注册号:

Registration number:

ITMCTR2024000772

最近更新日期:

Date of Last Refreshed on:

2024-12-03

注册时间:

Date of Registration:

2024-12-03

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

支气管哮喘中医证候时空演变规律和表征生物学的队列研究

Public title:

A cohort study on the spatio-temporal evolution pattern and representational biology of bronchial asthma evidence in traditional Chinese medicine

注册题目简写:

BioSTEP Study

English Acronym:

BioSTEP Study

研究课题的正式科学名称:

支气管哮喘中医证候时空演变规律和表征生物学的队列研究

Scientific title:

A cohort study on the spatio-temporal evolution pattern and representational biology of bronchial asthma evidence in traditional Chinese medicine

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

范斐婷

研究负责人:

陈远彬

Applicant:

Fan Feiting

Study leader:

Chen Yuanbin

申请注册联系人电话:

Applicant telephone:

13925040131

研究负责人电话:

Study leader's telephone:

15920174645

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

fft41@163.com

研究负责人电子邮件:

Study leader's E-mail:

chenyuanbin110@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

广东省广州市大德路111号

研究负责人通讯地址:

广东省广州市大德路111号

Applicant address:

No. 111 Dade Road Guangzhou Guangdong Province China

Study leader's address:

No. 111 Dade Road Guangzhou Guangdong Province China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广东省中医院

Applicant's institution:

Guangdong Hospital of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

BE2024-306-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

广东省中医院伦理委员会

Name of the ethic committee:

Ethics Committee of Guangdong Hospital of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2024/11/1 0:00:00

伦理委员会联系人:

李晓彦

Contact Name of the ethic committee:

Li Xiaoyan

伦理委员会联系地址:

广东省广州市大德路111号

Contact Address of the ethic committee:

No. 111 Dade Road Guangzhou Guangdong Province China

伦理委员会联系人电话:

Contact phone of the ethic committee:

020-81887233

伦理委员会联系人邮箱:

Contact email of the ethic committee:

llbgs@gzucm.edu.cn

研究实施负责(组长)单位:

广东省中医院

Primary sponsor:

Guangdong Hospital of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

广东省广州市大德路111号

Primary sponsor's address:

No. 111 Dade Road Guangzhou Guangdong Province China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

Country:

China

Province:

Guangdong Province

City:

单位(医院):

广东省中医院

具体地址:

广东省广州市大德路111号

Institution
hospital:

Guangdong Hospital of Traditional Chinese Medicine

Address:

No. 111 Dade Road Guangzhou Guangdong Province China

经费或物资来源:

省部级(省部共建湿证国家重点实验室);省部级(广东省中医证候临床研究重点实验室);院级(中山市中医院岐黄学者·省名中医卢传坚教授工作室免疫学科联合研究项目)

Source(s) of funding:

the State Key Laboratory of Dampness Syndrome of Chinese Medicine (Grant no. SZ2021ZZ42)

研究疾病:

支气管哮喘

研究疾病代码:

Target disease:

bronchial asthma

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

队列研究

Cohort study

研究所处阶段:

Study phase:

其它

Others

研究目的:

1. 开展全国多中心支气管哮喘前瞻性大型队列研究,探索支气管哮喘(包括不同哮喘类型、表型)疾病发生发展过程中的中医证候时空演变规律、危险因素及结局转归;整合中西医多源异构数据,构建哮喘急性发作和重症哮喘的风险预测模型。 2. 按访视计划定期采集支气管哮喘患者的痰液和血液样本,分析疾病发展过程中与证候表征相关的多维生物学指标及潜在生物标志物,探索支气管哮喘中医证候演变规律下的证候本质和药物干预潜在的作用靶点。

Objectives of Study:

1. To conduct a national multi-centre prospective large-scale cohort study on bronchial asthma to explore the temporal and spatial evolution of Chinese medicine symptoms risk factors and outcome regression in the course of bronchial asthma; to integrate Chinese and Western medicine multi-source heterogeneous data to construct a risk prediction model for acute asthma exacerbation. 2. Collect sputum and blood samples from bronchial asthma patients regularly according to the visit scheduled; analyse the multidimensional biological indicators and potential biomarkers related to the symptoms during the disease process and explore the nature of the symptoms under the evolution of Chinese medicine symptoms in bronchial asthma and the potential targets of drug intervention.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1)18 岁≤年龄<75 岁,男女不限; 2)符合支气管哮喘或健康人群的诊断标准; 3)自愿参加本研究并签署知情同意书

Inclusion criteria

(1) 18 years old ≤ age <75 years old male and female; (2)Meet the diagnostic criteria of bronchial asthma or healthy people; (3) Voluntarily participate in the study and sign the informed consent form.

排除标准:

1)合并支气管扩张症、慢性肺源性心脏病、肺恶性肿瘤、肺间质纤维化、 活动性肺结核、嗜酸性粒细胞性肺炎等其它严重肺部疾病; 2)合并类风关、红斑狼疮等自身免疫性疾病,且病情不稳定; 3)合并寄生虫感染、剥脱性皮炎、天疱疮、猩红热、慢性粒细胞性白血病、 霍奇金病、慢性肾上腺皮质功能减退等可引起血清嗜酸性粒细胞升高的疾病; 4)合并肺曲霉病、高 IgE 综合征、IgE 型多发性骨髓瘤等可引起血清总 IgE 升高的疾病; 5)合并其它脏器(如心、脑、肝、肾等)较严重的原发性疾病或恶性肿瘤; 6)精神类疾病患者或其他原因不能合作者。

Exclusion criteria:

(1) Combination of other serious lung diseases such as bronchiectasis chronic pulmonary heart disease lung malignancy interstitial fibrosis active tuberculosis eosinophilic pneumonia and so on; (2) Combination of autoimmune diseases such as rheumatoid lupus erythematosus and other unstable conditions; 3)Combination of parasitic infection exfoliative dermatitis aspergillosis scarlet fever chronic granulocytic leukaemia Hodgkin's disease chronic adrenocortical hypoplasia and other diseases that can cause elevated serum eosinophils; (4) Combination of pulmonary aspergillosis high IgE syndrome IgE type multiple myeloma and other diseases that can cause elevation of total serum IgE; (5) Combined with other organs (such as heart brain liver kidney etc.) more serious primary diseases or malignant tumours; (6) Patients with mental illness or other reasons for not being able to co-operate.

研究实施时间:

Study execute time:

From 2024-12-05

To      2026-12-05

征募观察对象时间:

Recruiting time:

From 2024-12-05

To      2026-12-05

干预措施:

Interventions:

组别:

过敏性哮喘组

样本量:

500

Group:

Allergic Asthma Group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

非过敏性哮喘组

样本量:

500

Group:

Non-allergic asthma group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

健康组

样本量:

50

Group:

health group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

样本总量 Total sample size : 1050

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

广东省

市(区县):

Country:

China

Province:

Guangdong Province

City:

单位(医院):

惠州市第三人民医院

单位级别:

参与单位

Institution/hospital:

The Third People's Hospital of Huizhou

Level of the institution:

Participating unit

国家:

中国

省(直辖市):

广东省

市(区县):

Country:

China

Province:

Guangdong Province

City:

单位(医院):

东莞市中西医结合医院

单位级别:

参与单位

Institution/hospital:

Dongguan Hospital of Integrative Medicine

Level of the institution:

Participating unit

国家:

中国

省(直辖市):

湖南省

市(区县):

Country:

China

Province:

Hunan Province

City:

单位(医院):

湖南省直中中医院

单位级别:

参与单位

Institution/hospital:

Hunan Provincial Central Hospital

Level of the institution:

Participating unit

国家:

中国

省(直辖市):

广东省

市(区县):

Country:

China

Province:

Guangdong Province

City:

单位(医院):

湛江市第二中医医院

单位级别:

参与单位

Institution/hospital:

Zhanjiang No.2 Chinese Medicine Hospital

Level of the institution:

Participating unit

国家:

中国

省(直辖市):

广东省

市(区县):

Country:

China

Province:

Guangdong Province

City:

单位(医院):

中山市中医院

单位级别:

参与单位

Institution/hospital:

Zhongshan Hospital of Traditional Chinese Medicine

Level of the institution:

Participating unit

国家:

中国

省(直辖市):

山东省

市(区县):

Country:

China

Province:

Shandong Province

City:

单位(医院):

山东省烟台市中医院

单位级别:

参与单位

Institution/hospital:

Yantai Hospital of Traditional Chinese Medicine Shandong Province

Level of the institution:

Participating unit

国家:

中国

省(直辖市):

四川省

市(区县):

Country:

China

Province:

Xichuan Province

City:

单位(医院):

成都市中西医结合医院

单位级别:

参与单位

Institution/hospital:

Chengdu Combined Traditional Chinese and Western Medicine Hospital

Level of the institution:

Participating unit

国家:

中国

省(直辖市):

广州市

市(区县):

Country:

China

Province:

Guangdong Province

City:

单位(医院):

广东省中医院

单位级别:

试验主办单位

Institution/hospital:

Guangdong Hospital of Traditional Chinese Medicine

Level of the institution:

Trial organiser

国家:

中国

省(直辖市):

广东省

市(区县):

Country:

China

Province:

Guangdong Province

City:

单位(医院):

广州市番禺区中医院

单位级别:

参与单位

Institution/hospital:

Guangzhou Panyu District Hospital of Traditional Chinese Medicine

Level of the institution:

Participating unit

国家:

中国

省(直辖市):

广东省

市(区县):

Country:

China

Province:

Guangdong Province

City:

单位(医院):

广州市白云区第二人民医院

单位级别:

参与单位

Institution/hospital:

Guangzhou Baiyun District Second People's Hospital

Level of the institution:

Participating unit

测量指标:

Outcomes:

指标中文名:

肺功能指标

指标类型:

次要指标

Outcome:

Lung function indicators

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

抑郁自评工具量表

指标类型:

次要指标

Outcome:

PHQ-9

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

ACT量表

指标类型:

主要指标

Outcome:

ACT scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

广泛性焦虑量表

指标类型:

次要指标

Outcome:

GAD-7

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医四诊信息采集表

指标类型:

次要指标

Outcome:

Information Collection Form for Four Consultations of Chinese Medicine Practitioners

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

嗜酸粒细胞计数

指标类型:

次要指标

Outcome:

eosinophil count

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医湿证评估量表

指标类型:

次要指标

Outcome:

Chinese Medicine Dampness Assessment Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医湿证核心症征信息采集表

指标类型:

次要指标

Outcome:

Information Collection Form for Core Symptoms of Dampness in Chinese Medicine

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医体质量表

指标类型:

次要指标

Outcome:

Chinese Medicine Body Mass Chart

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

总IgE浓度

指标类型:

次要指标

Outcome:

Total IgE concentration

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

过敏原指标

指标类型:

次要指标

Outcome:

Allergen indicators

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血浆

组织:

Sample Name:

plasma

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

血清

组织:

Sample Name:

serum

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

痰液

组织:

Sample Name:

sputum

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 75
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

无需随机

Randomization Procedure (please state who generates the random number sequence and by what method):

Not need to random

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

非共享,数据将以论文形式发表

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The data is not shared and will be published in the form of a paper

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统